Did you know?

Nov 2, 2023 · Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ... Editas Medicine (EDIT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.57 per share a year ago. These figures ...Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Editas Medicine (EDIT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $0.57 per share a year ago. These figures ...The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.The genome editing company's revenue was $6.3 million. That's rather impressive for a clinical-stage biotech, and well up from the roughly $379,000 Editas posted in the second quarter of 2021. Net ...Nonetheless, the filing did say that Editas already raised $163.3 million from selling preferred stock to private investors like Bill Gates and Google Ventures, along with other backers like Sun ...12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. It's been a tough year for Editas Medicine (EDIT-0.26%) so far. As of the market close on Monday, the stock was down 42%. But shares of Editas were rebounding by 8.2% as of 11:25 a.m. EST on ...In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial ...Moreover, the 36-month beta value for EDIT is 1.79. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 8 as “hold,” and 1 as “sell.” The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $5.41 above the current market price.Nov 30, 2023 · View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Find out the current price target and stock forecast for Editas Medicine ... Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85 ...Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Jun 28, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... Find out the direct holders, institutional holders and mutual fund holders for Editas Medicine, Inc. (EDIT).View the real-time EDIT price chart on Robinhood, Editas Medicine stock live quote and latest news. You can buy and sell Editas Medicine (EDIT) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details.The analyst also gave the stock a price target of $20. Editas Medicine's share price as of the closing of business day yesterday was $40.98. And even after today's sell-off, Editas Medicine stock ...Phil Nadeau’s Buy rating for Editas Medicine’s stock is premised on a variety of factors. Key among these is the company’s strong financial position, with reported cash reserves of $446 ...Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.Based on short-term price targets offered by 13 analysts, the average price target for Editas Medicine comes to $13.85. The forecasts range from a low of $7.00 to a high of $30.00. The average ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Stock price history for Editas Medicine (EDIT). Highest eGet Editas Medicine Inc (EDIT.OQ) real-time stock quotes Editas Medicine Announces Pricing of Offering of Common Stock 06-15 - 2 views Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial EDIT-301 was well-tolerated and demonstrated a safety profile consi 06-09 - 1 viewCheck out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stock Yes, Editas Medicine is a publicly traded company. What is the Ed Editas Medicine, Inc. ( EDIT) NASDAQ: EDIT · IEX Real-Time Price · USD Add to Watchlist Buy EDIT 10.58 +0.09 (0.86%) At close: Nov 24, 2023, 1:00 PM 10.53 …Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Ge

May-11-23 10:32AM. Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress. (GlobeNewswire) May-10-23 06:02AM. Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%. (Simply Wall St.)View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, …Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...Editas Medicine (EDIT) stock price prediction is 21.694681385149 USD. The Editas Medicine stock forecast is 21.694681385149 USD for 2024 November 30, ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.DraftKings (NASDAQ:DKNG) was upgraded to Buy from Neutral at MoffettNathanson, with its price target raised by $6.00 to $37.00. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Summary of all time highs, changes and price drops for Edit. Possible cause: Price is a widely used stock evaluation measure. Find the latest Price .